• Gene fusion; HGNC; HGNC:3819; FOXO1 + HGNC; HGNC:8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=17547718).
  

PubMed=17547718; DOI=10.1111/j.1749-0774.2007.00029.x
Satoshi Ohi;
Characterization, anticancer drug susceptibility and atRA-induced growth inhibition of a novel cell line (HUMEMS) established from pleural effusion of alveolar rhabdomyosarcoma of breast tissue.
Hum. Cell 20:39-51(2007)

PubMed=20712710; DOI=10.1111/j.1749-0774.2010.00086.x
Minako Suzuki, Noriko Tominaga, Yoshiaki Ide, Akihiro Ohyama, Taka Nakahara, Hiroshi Ishikawa, Akira Tanaka, Izumi Mataga;
Establishment and characterization of the rhabdomyosarcoma cell line designated NUTOS derived from the human tongue sarcoma: special reference to the susceptibility of anti-cancer drugs.
Hum. Cell 23:65-73(2010)

PubMed=23882450; DOI=10.3389/fonc.2013.00183; PMCID=PMC3713458
Ashley R.P. Hinson, Rosanne Jones, Lisa E.S. Crose, Brian C. Belyea, Frederic G. Barr, Corinne Mary Linardic;
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Front. Oncol. 3:183.1-183.12(2013)

PubMed=23665679; DOI=10.1038/onc.2013.129
Elizabeth I. Sokolowski, Claire B. Turina, Ken Kikuchi, David M. Langenau, Charles Keller;
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.
Oncogene 33:1877-1889(2014)